TITLE-Substituted indole derivatives for the treatment of immunological disorders
Protein kinase C theta inhibitor
WO 2012156936, 22.11.2012, Novartis AG
GENERAL STRUCTURE
DESCRIBED IS
Phosphoric acid mono-[3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1 -yl]-4-(7-methyl-1 H-indol-3-yl)-2,5-dioxo-2,5-dihydro-pyrrol-1 -ylmethyl] ester
1H-NMR (400 MHz, DMSO-d6): 12.10 (s, 1 H), 8.08 (d, 1 H), 7.65-7.61 (m, 2H), 7.44 (f, 1 H), 7.20 (s, 1 H), 7.06 (f, 1 H), 6.74 (d, 1 H), 6.43 (f, 1 H), 6.00 (d, 1 H), 5.29 (d, 2H), 3.87-3.01 (m, 6H), 2.37 (s, 3H), 0.97-0.62 (m, 4H).
31P-NMR (162 MHz, DMSO-d6): -6.0.
LCMS: [M+1]+ = 574.0, Rt (1) = 1.77 min., Rt (2) = 0.71 min.
Descibed is a crystalline form of phosphoric acid mono-[3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1- yl]-4-(7-methyl-1 H-indol-3-yl)-2,5-dioxo-2,5-dihydro-pyrrol-1-ylmethyl] ester, especially the mono-hydrate, which preferably has an X-ray powder diffraction pattern with at least one, preferably two, more preferably three, even more preferably four, especially five, most preferably all of the following peaks at an angle of refraction 2 theta (Θ) of 9.525, 16.356, 17.091 , 18.005, 20.859, each ± 0.2
